Cornelis Wesdorp, serving as President and CEO of Digital Health at RadNet, Inc. (NASDAQ:RDNT), executed a transaction involving the sale of 4,750 shares of the company's common stock on June 16, 2026. The total value of this divestment was approximately $276,022, based on a per-share price of $58.11.
Following the completion of this transaction, Mr. Wesdorp's direct holdings in RadNet common stock stand at 69,075 shares. The sale was formalized through a Form 4 filing submitted to the Securities and Exchange Commission.
The transaction price of $58.11 per share was notably above the stock's current trading level of $53.74. At the time of the report, RDNT was trading near its 52-week low of $50.76. The stock had experienced a decline of 7.68% over the preceding week.
While RadNet did not generate profitability over the last twelve months, financial analysts forecast that the company is expected to achieve profitability within the current year. These projections include an anticipated earnings figure of $0.51 per share.
In broader corporate developments, RadNet reported its first-quarter 2026 earnings results. The report highlighted record revenue and growth in adjusted EBITDA. However, the company's results fell short of earnings per share expectations for the period.
On the capital structure front, RadNet secured a $250 million incremental term loan through an amendment to its existing credit agreement. This new loan facility is scheduled to mature on April 18, 2031.
Additionally, the company is pursuing a $200 million incremental term loan to support growth initiatives. This financing is part of RadNet's strategy for acquisitions and organic expansion. The loan is also set to mature in 2031.
Regarding credit ratings, Moody’s Ratings downgraded RadNet's senior secured first lien bank credit facilities from Ba3 to B1. The downgrade was attributed to the inclusion of additional first lien debt within the capital structure. Despite this adjustment, the corporate family rating remains unchanged at B1, with a stable outlook maintained.
In technological advancements, DeepHealth, a wholly owned subsidiary of RadNet, announced the commercial availability of Reporting Pro. This solution is an AI-powered radiology reporting tool. The product integrates various features, including speech recognition and AI-generated impressions, into a single workflow.
These activities underscore RadNet's ongoing efforts to expand its financial resources and technological capabilities. The company's balance sheet and operational strategies remain central to its current market position.